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Abstract                                           . 11 
Objectives:  Low Frequency Electrical Muscle Stimulation (LF-EMS) may have the 12 
potential to reduce breathlessness and increase exercise capacity in the chronic 13 
heart failure population who struggle to adhere to conventional exercise. The study’s 14 
aim was to establish if a randomised controlled trial of LF-EMS was feasible. 15 
Design and setting: Double blind (participants, outcome assessors), randomised 16 
study in a secondary care outpatient cardiac rehabilitation program.  17 
Participants:  Severe heart failure patients (New York Heart Association class III-IV) 18 
with left ventricular ejection fraction <40% documented by echocardiography were 19 
eligible.  20 
Interventions: Participants were randomised(remotely by computer) to 8 weeks (5 x 21 
60 mins per week) of either LF-EMS intervention (4Hz, continuous, n=30) or SHAM 22 
placebo (skin level stimulation only, n=30) of the quadriceps and hamstrings 23 
muscles. Participants used the LF-EMS straps at home and were supervised weekly  24 
Outcome measures:   Recruitment, adherence and tolerability to the intervention 25 
were measured during the trial as well as physiological outcomes (primary outcome: 26 
6 minute walk, secondary outcomes: quadriceps strength, quality of life and physical 27 
activity).  28 
Results: Sixty of 171 eligible participants (35.08%) were recruited to the trial. 12 29 
(20%) of the 60 patients (4 LF-EMS, 8 SHAM) withdrew. Forty one patients (68.3 %), 30 
adhered to the protocol for at least 70% of the sessions. The physiological measures 31 
indicated no significant differences between groups in 6 minute walk 32 
distance,(P=0.13) and quality of life, (P=0.55) although both outcomes improved 33 
more with LF-EMS. 34 
Conclusion: Severe heart failure patients can be recruited to and tolerate LF-EMS 35 
studies.  A larger Randomised Controlled Trial (RCT) in the advanced heart failure 36 
population is technically feasible, although adherence to follow-up would be 37 
challenging. The preliminary improvements in exercise capacity and quality of life 38 
were minimal and this should be considered if planning a larger trial.  39 
Trial registration number: ISRCTN16749049 40 
 41 
Strengths and Limitations 42 
1. To our knowledge, this was the first study to evaluate the design of a study into 43 
LF-EMS in advanced (NYHA III-IV) heart failure patients 44 
2. Analysis of recruitment, retention and adherence in this hard to reach group 45 
contributes useful knowledge to the heart failure literature on how practical 46 
exercise interventions could be implemented. 47 
3. This study was a real-world feasibility study. Advanced heart failure patients 48 
were recruited when deemed eligible by experienced clinicians based on 49 
available information. This approach can be subjective and lead to variability in 50 
disease severity in our sample. However this is in keeping with the pragmatic 51 
aim of our trial and provides external validity to our findings. 52 
4. This study had a small sample size, and was not powered or designed to 53 
assess the effects of LF-EMS in advanced heart failure. The findings should 54 
therefore be considered preliminary.  55 
  56 
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Introduction 57 
 58 
Chronic Heart Failure (CHF) affects approximately 26 million people worldwide, 1 59 
and is associated with a poor prognosis; 30- 40% of patients diagnosed with heart 60 
failure die within a year. 2  Patients in New York Heart Association (NYHA) class 61 
III/IV are unable to perform the simplest daily activities, become depressed and have 62 
a poor quality of life.3  63 
Regular aerobic exercise reduces breathlessness and muscle dysfunction for 64 
individuals with CHF whilst improving exercise capacity.4,5,6  According to the 65 
ExTraMATCH meta-analysis,7 exercise training leads to a 35% relative reduction in 66 
mortality, similar to the effects of beta-blockers8 and ACE inhibitors.9  However, 67 
those with advanced CHF are often so limited that they are unable to gain the holistic 68 
benefits of exercise.4,7  69 
Electrical Muscle Stimulation (EMS) may provide an alternative rehabilitative 70 
therapy for this group.  In patients with mild to moderate CHF, EMS can improve 71 
muscle strength of the legs, exercise capacity and quality of life. 10,11,12 Low 72 
frequency (4-5Hz) electrical muscle stimulation (LF-EMS) produces shivering-like 73 
sub-tetanic muscle contractions that can stimulate an aerobic response equivalent to 74 
51% of maximal oxygen uptake.13 Therapeutic levels of aerobic exercise can thus be 75 
achieved passively by LF-EMS,14 and it has been shown to be comfortable and well 76 
tolerated in healthy individuals and those with mild to moderate CHF. 15,16 However, 77 
the impact of LF-EMS in advanced heart failure (NYHA class III/IV) patients is 78 
currently unknown.  As advanced heart failure patients have shown poor uptake and 79 
adherence to intervention studies,17 a preliminary study was needed to determine the 80 
feasibility of LF-EMS in this patient cohort prior to the development of a large-scale 81 
definitive trial.  82 
Based upon recommendations for good practice in the design of pilot and 83 
feasibility studies 18 this study was undertaken with the following aims: To (a) test the 84 
robustness of the study protocol for a potential future trial, (b) estimate rates of 85 
recruitment, consent and retention, (c) determine the tolerability of the LF-EMS 86 
intervention and the effectiveness of the sham placebo in the NYHA III/IV CHF 87 
population, and (d) gain initial estimates of the efficacy of LF-EMS for all potential 88 
primary outcomes. This can be used for sample size calculations in future 89 
substantive trials.  90 
  91 
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Methods 92 
Experimental Design 93 
This feasibility study used a double blind parallel group randomised control 94 
design.  Participants were randomised to either LF-EMS or ‘sham’ placebo for a 95 
period of eight weeks and blinded to group allocation.  Outcomes were assessed at 96 
baseline (pre randomisation), eight weeks and 20 weeks follow-up. 97 
Recruitment and screening 98 
Between October 2013 and March 2015, University Hospital Coventry and 99 
Warwickshire, (UHCW) Hospital NHS Trust heart failure clinics lists were screened 100 
for patients fulfilling the eligibility criteria for the study.  Sixty eligible participants were 101 
recruited.  The study conformed to the Declaration of Helsinki and was approved by 102 
the local NHS Ethics Committee.  All participants provided written informed consent. 103 
Randomisation 104 
The trial statistician, in conjunction with Warwick Clinical Trials Unit generated 105 
the randomisation sequence remotely (by computer) using permuted block 106 
randomisation.  Group allocation was concealed from outcomes assessors and 107 
participants.  108 
Participants 109 
Male and female adults, >18 years old, with stable CHF, documented by 110 
echocardiography of left ventricular systolic dysfunction (ejection fraction < 40%) 111 
were eligible for the study.  All participants had New York Heart Association (NYHA) 112 
functional class III-IV symptoms as judged by an experienced heart failure 113 
cardiologist.  Participants were required to be medically stable, defined as the 114 
absence of hospital admission or alterations in medical therapy within the preceding 115 
two weeks.  Exclusion criteria for safety and practical reasons were: (1) presence of 116 
implantable cardiac devices, (2) serious cardiac arrhythmias,(3) neurological 117 
disorders or previous stroke significant enough to limit exercise, (4) orthopaedic  118 
problems that prevented walking, (5) neuromuscular disease, (6) dementia or (7) a 119 
mid-thigh circumference of more than 50cm (due to the size of the LF-EMS straps). 120 
LF-EMS Stimulation  121 
The LF-EMS equipment (Biomedical Research Limited, Galway, Ireland) 122 
consisted of a pair of neoprene straps containing built-in adhesive gel electrodes.   123 
The equipment is CE marked under the European Medical Device Directive.  The 124 
stimulator current waveform was designed to produce rhythmical contractions in the 125 
leg muscle groups occurring at a pulse frequency of 4-5Hz (pulse width: 620µs).  126 
The maximum peak output pulse current used was 140mA. 127 
LF-EMS intervention 128 
Participants used the LF-EMS or sham placebo for one hour, five times a 129 
week, for eight consecutive weeks.  Of the five hourly sessions per week, four were 130 
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completed unsupervised in the participant’s own home.  The remaining session was 131 
conducted in a cardiac rehabilitation outpatient setting under the supervision of an 132 
exercise physiologist.   The LF-EMS technology was retrospectively interrogated (i.e. 133 
at the weekly supervised sessions) to report date, frequency, duration and 134 
stimulation intensity. 135 
‘Sham’ Placebo intervention 136 
In the sham arm of the study, participants were provided with identical straps 137 
and electrodes.  In contrast to the LF-EMS group the controller was programmed to 138 
deliver a very low level of stimulation (Frequency: 99Hz, pulse width: 150µs, 139 
maximum current amplitude: 7.3mA).  This provided sensory input to the skin surface 140 
but little or no muscle activation.  Participants in the sham group had the same 141 
induction, supervision and follow-up as the intervention arm. 142 
Outcome Measures 143 
Feasibility criteria  144 
 In relation to the design of pilot and feasibility studies, Thabane et al,19 145 
recommends stipulating criteria for success ‘a priori’.  The feasibility criteria were: 146 
1.   Recruitment rate – At least 40% of eligible participants recruited to the trial 147 
 148 
2.   Retention – no more than 33% of participants drop out during the intervention 149 
period. 150 
 151 
3.   Adherence – 66% of participants tolerate the intervention and adhere to the 152 
protocol for ≥70% of the intervention period. 153 
 154 
4.   Placebo efficacy- Participants would be able to guess their group allocation 155 
no more often than would be expected by chance. 156 
 157 
Primary outcome  158 
Six Minute Walk Test (6MWT). 159 
The 6MWT was conducted in accordance with the American Thoracic Society 160 
(ATS) guidelines.20  Participants were instructed to walk as far as possible in six 161 
minutes along a 30m, flat, obstacle free corridor, turning 180 degrees at the end of 162 
every 30m.   Standardised instructions and verbal encouragement were given.   163 
Secondary outcomes 164 
Isometric muscle strength 165 
A hand held dynamometer (MicroFET2 Torque/Force indicator, Hoggan 166 
Health Industries, Utah, US) validated for assessing functional leg strength in elderly 167 
populations was used.21  Participants sat in an elevated chair and were  instructed to 168 
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maximally extend the knee while the assessor provided an equal and opposite 169 
resistive force, against the lower shin.    Mean force generated was measured in 170 
Newtons. 171 
Quality of Life: Minnesota Living with Heart Failure Questionnaire (MLHFQ) 172 
The MLWHF questionnaire is a disease validated questionnaire,22  that has 173 
been extensively used in heart failure studies.   Questionnaire scores range from 0 to 174 
105, with higher scores reflecting lower Quality of life. Participants were asked to 175 
answer each question based on their perception of health in the week previous to 176 
testing. 177 
Physical Activity levels 178 
Physical activity levels were measured by the Bodymedia© SenseWear Pro3 179 
Armband.  The multi-plane accelerometer was worn continuously for the seven days 180 
prior to testing to determine Total Energy Expenditure (TEE) per 24hr period was 181 
used as the main indicator of physical activity.   182 
LF-EMS acceptability questionnaire 183 
At the end of the trial participants were given a brief questionnaire used in previous 184 
LF-EMS studies,13,14 to collect feedback on the acceptability of using LF-EMS 185 
regularly. Questions used the likert scale and covered ease of use, comfort, 186 
tolerability and overall satisfaction. 187 
Safety: Blood test 188 
Venous blood samples were taken at baseline, four weeks and eight weeks to 189 
assess creatine kinase (CK), urea, and electrolytes. Participants would discontinue 190 
the trial if levels exceeded the upper limit of normal reference ranges 191 
Data analysis 192 
Data analyses for the feasibility objectives of this study were descriptive, 193 
based on the pre-determined levels specified above.  Confidence intervals (set at 194 
95%) were calculated for all secondary outcome measures in both groups and paired 195 
two-sample t-test conducted for between group comparisons.    Intent-to-treat (ITT) 196 
analysis was employed in this study as is recommended for clinical trials.24  197 
 198 
199 
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Results 200 
Feasibility criteria outcomes 201 
Recruitment 202 
There were 171 eligible participants identified in the Coventry and 203 
Warwickshire area from November 2013 - April 2015.  Sixty of 171 eligible 204 
participants (35.08%) were recruited to the trial.  Participants were randomised and 205 
started on the trial during this period and were followed up until data collection 206 
finished in August 2015.  Participant characteristics are presented in Table 1. 207 
  208 
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Table 1.  Baseline demographic and clinical characteristics of the LF-EMS and sham 209 
placebo groups.  Data presented as mean ± SD or absolute number and percent.      210 
Demographics   LF-EMS (n-30)  Sham (n=30) 211 
   n Male    20 (66%)   22 (73%) 212 
  Age (yrs)    66.5 ± 7.8   66.8 ± 13.5 213 
  Body Mass Index (kg/m2)  30.1 ± 4.9   27.8 ± 4.8 214 
Comorbidities 215 
  Prev MI/PCI/CABG  17 (56%)   11 (36%)  216 
  Diabetes    12 (40%)   10 (33%) 217 
  COPD    9 (30%)   8 (26%) 218 
  AF     20 (66%)   16 (53%) 219 
  Hypertension   13 (43%)   10 (33% 220 
  CKD     5 (16%)   13 (43%) 221 
Clinical 222 
  NT-pro-BNP (pg/mL)  3086  3746   2046  2545 223 
  Creatinine (mol/L)  108  49   113  39 224 
  LVEF %    39  11*   22  12** 225 
  BPsys (mmHg)   118 ± 16   126 ± 17 226 
  BPdia (mmHg)   69 ± 9    74 ± 14 227 
  NYHA III     24 (80%)   22 (73%) 228 
  NYHA IV     6 (20%)   8 (26%) 229 
 230 
NT-pro-BNP (pg/mL),N-terminal pro B-type natriuretic peptide; LVEF; left ventricular 231 
ejection fraction; BPsys (mmHg), systolic blood pressure; BPdia (mmHg), diastolic 232 
blood pressure; NYHA, New York Heart association; MI, myocardial infarction;  PCI, 233 
percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; 234 
COPD, chronic obstructive pulmonary disease; AF, atrial fibrillation; CKD, chronic 235 
kidney disease;  236 
*n=10.Ejection fraction could not be accurately assessed in all patients due to poor 237 
body habitus/atrial fibrillation. An experienced cardiac sonographer made an ‘eyeball’ 238 
assessment of poor left ventricular function for all other participants 239 
**n=5. See previous comments. 240 
 241 
 242 
  243 
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Retention 244 
Twelve of the 60 participants (4 LF-EMS, 8 sham) (20%) withdrew and did not 245 
finish the intervention period (See Fig 1).  Of these, only three found the intervention 246 
intolerable (1 LF-EMS, 2 sham).  Other reasons for dropout were: deterioration in 247 
health (n= 6) family problems (n=2) and implantation of a cardioverter defibrillator 248 
(ICD) (n=1).  Only 22 (45%) of those completing the intervention period returned for 249 
follow-up testing at 20 weeks.  Reasons for non-follow-up were: deterioration in 250 
health (n=9), excluded due to implantation of cardiac resynchronisation therapy 251 
device (n=2), declined to take part without further explanation (n=13), and could not 252 
be contacted after repeated attempts (n= 3). 253 
  254 
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 274 
Figure 1. Flow diagram of a single centre blinded parallel group randomised 275 
feasibility trial of electrical muscle stimulation versus sham placebo in severe heart 276 
failure patients.  277 
 278 
 279 
 280 
  281 
   Completed Intervention (n=26)  
 Withdrew due to illness/death 
(n=2)  
cramp) n=1 
 
   Allocated to LF-EMS 
intervention (n=30) 
 Received allocated intervention 
(n=29) 
 Did not receive allocated 
intervention (n=1, ill health)  
   Completed Intervention (n=22) 
 Withdrew due to illness (n=3) 
 Could not tolerate straps (n=2) 
 Family problems (n=2) 
 
   Allocated to sham placebo 
intervention (n=30) 
 Received allocated intervention 
(n=29) 
 Did not receive allocated 
intervention (n=1, ill health)  
    Followed up (n=10) 
Unable Due to illness (n=3) 
-up (n=6) 
 
 
Allocation 
Post 
Intervention 
At 8 weeks  
    Followed-up (n= 12) 
 
-up (n=7) 
 
Follow-up at  
20 weeks 
 
Assessed for eligibility 
(n= 720) Excluded (n=660) 
   Not meeting inclusion 
criteria (n=549) 
   Eligible, but declined to 
participate (n=109) 
   Other reasons (n=2) 
Randomised 
(n=60) 
Screening 
 
BMJ Open manuscript- LF-EMS in advanced CHF 
11 
 
Adherence 282 
 Forty one (85.4 %) of the 48 participants (22-LF-EMS, 19-SHAM) who 283 
completed the intervention period (68.3% of the total sample) adhered to the strict 284 
protocol for the majority (>70%) of the eight weeks.  Interrogation of the LF-EMS 285 
controllers revealed that participants in the LF-EMS group became more tolerant to 286 
the intervention; mean stimulation intensity increased from 57.79mA (95%CI: 51.16 287 
to 64.42) during week 1 of the study to 84.86mA (95%CI: 75.44 to 94.28) by week 8, 288 
an improvement of 46.5%. 289 
 ‘Sham’ Placebo  290 
The sham placebo for the study appeared to be convincing as only 61% of 291 
participants guessed their treatment group correctly.  The 95% confidence interval 292 
for the proportion of participants guessing correctly was (46% to 74%) and thus not 293 
significantly different from 50% which would be expected by chance.  Furthermore, 294 
participants demonstrated an inclination to guess that they were randomised to LF-295 
EMS regardless of group allocation. 296 
Safety 297 
No abnormalities were detected in CK, urea or electrolytes taken before, 298 
during or after the study.  Likewise, no adverse events due to the intervention were 299 
recorded in either group.  300 
Primary outcome- 6-minute walk test 301 
Non-significant improvements after LF-EMS (8 week time point) and sham groups 302 
were observed in 6 MWD with a mean increase from baseline of 24m (P=0.13)in the 303 
LF-EMS group (Table 2.) 304 
Secondary outcomes 305 
Table 2 shows the mean values of the secondary outcome measures at each 306 
time point.  There were no significant differences between groups in the change from 307 
baseline for any of the secondary outcome variables (Table 3). There was a non-308 
significant improvement in quality of life in both groups. 309 
 310 
 311 
  312 
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Table 2: Outcome measurements – Time point averages and 95% confidence 313 
intervals (CI)  314 
Outcome Time point LF-EMS Sham 
Mean 6 
MWD 
(metres) 
[95% CI] 
 
Baseline 
(n) 
283 [237 – 328] 
29 
290 [243 – 337] 
29 
8 weeks 
(n) 
312 [262 – 362] 
26 
318 [270 – 365] 
22 
20 weeks 
(n) 
257 [173 – 342] 
12 
226 [126 – 325] 
10 
(Mean leg 
strength 
(newtons) 
[95% CI] 
 
Baseline 
(n) 
234.3 [196.5 – 272.] 
29 
297.5 [253 – 342] 
29 
8 weeks 
(n) 
224.9 [187.5 – 262.3]  
25 
321 [267.8 – 374.3] 
22 
20 weeks 
(n) 
181.6 [131.7 – 231.5] 
11 
207.1 [148.6 – 265.7] 
10 
Mean 
QoL 
(score) 
 [95% CI] 
 
Baseline 
(n) 
53.1 [42.7 – 63.5] 
28 
50 [40 – 60.1] 
29 
8 weeks 
(n) 
43.9 [34.2 – 53.5] 
25 
43.1 [30.9 – 55.3] 
22 
20 weeks 
(n) 
51.7 [31.6 – 71.8] 
12 
37.0 [16.9 – 57] 
10 
Mean 
TEE 
(joules) 
[95% CI] 
 
Baseline 
(n) 
63,438 [56,170 – 
70,705] 
25 
65,371 [59675 – 
71,067] 
27 
8 weeks 
(n) 
59,783  [51,094 – 
68,471] 
19 
59,687 [50,630 – 
68,745] 
17 
20 weeks 
(n) 
61,878 [53,345 – 
70,410] 
7 
63,541 [55,795 – 
71,287] 
6 
6 MWD, 6 minute walk distance, QoL, quality of life; TEE, Total Energy Expenditure 315 
  316 
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Table 3: -Changes from baseline averages and 95% confidence intervals (CI) 317 
Outcome Time point LF-EMS Sham p-value 
Mean 6 
MWD 
(metres) 
[95% CI] 
Baseline to 8 
weeks 
(n) 
24 [9 – 40] 
 
26 
9 [-4 – 22] 
 
22 
0.1366 
Baseline to 20 
weeks 
(n) 
0 [-32 – 31] 
 
12 
-26.30  [-63 – 11] 
 
10 
0.2409 
 
(Mean leg 
strength 
(newtons) 
[95% CI] 
 
Baseline to 8 
weeks 
(n) 
-9.2 [-28.9  – 10.5] 
 
25 
6.0  [-19.3  – 31.4] 
 
22 
0.3244 
Baseline to 20 
weeks 
(n) 
-43.4  [-78.7 – -8.2] 
 
11 
-74.1  [-116.3  – -
31.9] 
 
10 
0.2223 
Mean QoL 
(score) 
 [95% CI] 
Baseline to 8 
weeks 
(n) 
-7.6 [-15.5 – 0.3] 
 
25 
-4.7    [-10.5 – 1.0] 
 
22 
0.5505 
Baseline to 20 
weeks 
(n) 
1.5 [-12.5 – 15.7] 
 
12 
-14.0   [-34 – 6] 
 
10 
0.1610 
Mean TEE 
(joules) 
[95% CI] 
Baseline to 8 
weeks 
(n) 
-4635  [-3963 – 
4692] 
 
19 
-8168  [-14,342  – -
1995] 
 
17 
0.5108 
Baseline to 20 
weeks 
(n) 
1686 [-6435 – 9809] 
 
7 
4177 [-7695  – 
16,050] 
 
6 
0.6634 
6 MWD, 6 minute walk distance; QoL, quality of life; TEE, Total Energy Expenditure 318 
 319 
 320 
 321 
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Acceptability questionairre 322 
Participants responses to the LF-EMS acceptability questionairre 323 
are summarised in table 4. The mean response to putting on the straps was 2 (‘quite 324 
easy’) and the overall mean satisfaction of participants with the intervention was 6 325 
out of 10. Mean responses to comfort, sensation, tolerabilty and continued use of LF-326 
EMS were between 3 (medium) and 4 (quite hard/unpleasant). 327 
 328 
Table 4. Mean responses to acceptability questionairre and standard deviations 329 
Question Mean 
response 
 
1. I found putting on the straps (1-easy, 5-hard) 2.0 (1.17) 
2. At the highest intensity I found the comfort level (1-
acceptable, 5-unacceptable) 
3.5 (1.19) 
3. Overall I found the sensation (1-pleasant, 5-unpleasant) 3.3 (1.13) 
4. I found putting on the LF-EMS for an hour (1-easy, 5-
hard) 
3.1 (1.08) 
5. I think I would find staying on a LF-EMS training routine 
(1-easy, 5-hard) 
3.4 (1.29) 
6. Overall satisfaction with LF-EMS as a way of improving 
your fitness (1-none,10 extremely satisfied) 
6.0 (1.94) 
 330 
Sample size calculation  331 
 332 
The point estimate from the study and the upper CI limit of this estimate were 333 
calculated.  The upper CI limit was used for the sample size calculation. For 334 
detecting the observed difference of 13.4 metres in this study a sample size of 240 335 
patients per group would be required.  However, a recent study 25 suggested that the 336 
minimal clinically important difference for 6MWD is 36 metres in mild-moderate CHF 337 
patients.  The clinical benefit of the effect size in this study should be considered 338 
before proceeding with a larger trial 339 
 340 
  341 
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Discussion  342 
The predetermined criteria for proceeding to a larger trial were achieved for dropout 343 
(20%), adherence (68.3%) and sham placebo efficacy (61.53% participants guessed 344 
correctly).  However, only 35.06% of eligible patients were recruited, below the target 345 
of 40%.  Initial outcome measures revealed no significant difference between 346 
intervention and placebo groups, although there was a non-significant improvement 347 
in 6MWD and quality of life after LF-EMS.   348 
 349 
Feasibility outcomes 350 
Recruitment 351 
Percentage uptake (35.06%) of eligible patients in the study was below the 352 
predetermined criteria of 40%.  This is similar to the poor uptake of conventional 353 
cardiac rehabilitation (CR) nationally in the UK: less than 40% of eligible heart failure 354 
patients accessed CR in the most recent National Audit of Cardiac Rehabilitation.26   355 
Retention/adherence/tolerance 356 
One strength of this study is the good level of adherence (68.3%) and 357 
retention (80%) compared with other clinical studies; In the HF-ACTION trial,27 only 358 
40% of patients in the exercise group (n=1159) reported adherence to recommended 359 
training volumes after three months.  This may have been because of the ease of 360 
independent use at home of LF-EMS, in combination with the weekly supervised 361 
sessions with an exercise physiologist. The patients recruited in the present trial 362 
were more debilitated yet they engaged more with LF-EMS than those in the HF-363 
ACTION trial, 27 suggesting that LF-EMS maybe more acceptable to this population 364 
than conventional exercise.   365 
The dropout at 3 months follow-up was lower than expected due to ill health, 366 
device implantation and apathy, and would be challenging to overcome in a larger 367 
trial. Strategies to combat dropout could include combining assessment with clinical 368 
patient appointments to ensure compliance or arranging home visits for some 369 
assessments. 370 
Feedback from the acceptability questionnaires may also be useful in 371 
curtailing dropout in a larger trial: the LF-EMS group generally thought that wearing 372 
the straps for an hour was ‘medium’ to ‘quite hard/unpleasant’. Continued use of a 373 
LF-EMS was deemed challenging also so it is possible that a reduced frequency of 374 
LF-EMS whilst still maintaining a sufficient dose e.g. 3 x 1 hr a week may enhance 375 
long term adherence. 376 
Tolerance to the LF-EMS intervention improved during the study.  Mean 377 
current intensity increased by 46% from week one to week eight.  This tolerance 378 
effect is in keeping with an earlier study by Crognale, et al,13 that showed a 20% 379 
increase in healthy active adults.  The active adults tolerated higher absolute 380 
stimulation levels than in this study, both before and after habituation, suggesting 381 
that advanced CHF patients are subjectively less tolerant to LF-EMS than a healthy 382 
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population. In addition, the user feedback collected seems to support this view.  383 
Vivodtzev and colleagues,28 examined factors determining tolerance of EMS in 384 
pulmonary patients.  The study reported that lower tolerance to EMS was associated 385 
with greater severity of condition, fat free mass and inflammatory response.  It is 386 
possible that the same is true in the CHF population but more research is needed to 387 
confirm this. 388 
Outcome Measures 389 
Baseline 6MWD was higher in our study sample than in other advanced heart failure 390 
studies.29 This may have been due to high variability because of a few outliers in 391 
each group. This reflects the subjective nature of the NYHA classification system. 392 
However, signs and symptoms of advanced heart failure were primarily the eligibility 393 
criteria for this study and not 6MWD.  In addition, the ≤300-m distance cutoff (below 394 
which our baseline mean falls) is often cited, as prognostically important and 395 
reflective of advanced disease in many investigations.30,31,32 The non-significant 396 
improvements in exercise capacity as measured by 6 minute walk were smaller than 397 
those in a meta-analysis of EMS in heart failure patients by Smart, Dieberg and 398 
Gialluria.10 These authors reported a combined improvement in 6MWD of 46.9m vs 399 
usual care or placebo, compared to the effect size of 13.2m in this study.  However, 400 
patients in this study were more symptomatic than those included in the meta-401 
analysis,10 and thus had a lower baseline exercise capacity (286m vs 342m.) 402 
Nevertheless the mean relative increase (5%) in walk distance of participants in the 403 
LF-EMS group is within the measurement error associated with this test,33 and 404 
probably should not be considered clinically significant.25 The extrapolation from 405 
these results that severe CHF patients are beyond help from EMS maybe premature; 406 
a longer training period maybe required to show meaningful changes in exercise 407 
capacity, particularly as some participants took longer to tolerate meaningful EMS 408 
intensities than others.  409 
 410 
Quality of life (MLHFQ) improved in both groups after the intervention.  This may, in 411 
part, relate to the psychosocial benefits of engaging with researchers regularly in the 412 
cardiac rehabilitation facility.34 The placebo effect of both interventions and its 413 
influence on patients’ perception of well-being should not be underestimated.  414 
   Based on previous research by Banerjee et al,15,16 and numerous high 415 
frequency EMS studies,35,36,12  improvement in leg strength after use of LF-EMS was 416 
expected.  The current trial however, showed no significant change in muscle 417 
strength.  Muscle wasting, prevalent in many advanced heart failure patients,37 could 418 
explain this observation.  The chronic impairment of muscle tissue caused by heart 419 
failure affects the muscle and skin nerve receptors and hence contractility of the 420 
weakened muscle.38  Participants with more functional leg muscles therefore, may 421 
have received greater stimulus to muscle tissue that others did for the same level of 422 
current intensity.  This suggests that LF-EMS may not be effective for all advanced 423 
CHF patients.   424 
Limitations 425 
The sample for this study was small as is recommended for feasability 426 
studies19 and this limits the external validity of our findings. Participants were 427 
deemed eligible for the study based on the judgment of experienced heart failure 428 
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clinicians using available knowledge. This may have led to greater variability in 429 
disease severity/limitation than was intended. The current amplitude (mA) stimulus 430 
intensity that participants chose to use was a limitation to the study design.  431 
Participants were instructed to adhere to the ‘maximum tolerable intensity’ during LF-432 
EMS sessions. Due to considerable individual differences in the subjective 433 
perception of discomfort associated with EMS, It is therefore likely that there was 434 
variability in the intensity that individuals received 435 
Conclusion 436 
As some of the predetermined feasibility criteria were met in this trial, a larger 437 
study into the effects of LF-EMS on advanced heart failure patients could be 438 
undertaken.  However this 'difficult to engage with' patient group would be very 439 
challenging to recruit and follow-up in sufficient numbers to provide definitive data on 440 
its efficacy. The improvements seen in this study in 6MWD, and quality of life 441 
measures, were not statistically significant.  Leg strength and physical activity levels 442 
showed no significant change.  A longer intervention period than 8 weeks could be 443 
considered, to give participants more time to adjust to the intervention. More 444 
investigation is required to determine which CHF patients are unresponsive to LF-445 
EMS due to severe muscle dysfunction. 446 
A larger trial may be feasible with this difficult population: however, it is 447 
unlikely that the non-significant improvement in exercise capacity and quality of life 448 
found in this pilot study justifies a larger pragmatic trial. 449 
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